MSQ Ventures
Edit

MSQ Ventures

https://www.msqventures.com/
Last activity: 24.01.2025
Active
CROSS-BORDER ADVISORY
MSQ Ventures is a NYC-based cross-border advisory firm that bridges the healthcare and emerging technology industries globally by offering our deep knowledge and local insight of the domestic market. We manage our clients’ cross-border transaction processes including licensing, M&A, fundraising, joint ventures and other strategic partnerships from our offices in New York, Los Angeles, Beijing, Shanghai, and Shenzhen.

EXPERIENCED TEAM
MSQ Ventures was founded by a group of Wall Street and healthcare veterans with deep insight into the healthcare landscape in China, the U.S. and Europe. Leveraging our vast network in China, we bring strong healthcare/technology research capability, extensive cross-border transaction experience, local knowledge, and a deep-rooted relationship with the corporate and investment community.

PROCESS DRIVEN
We offer our clients quality market research and a customized strategy in a comprehensive manner essential for a successful transaction. From different region market understanding to candidate screening and deal negotiation, our team focuses on efficiency and guides our clients through the entire process.
Mentions
3
Location: United States, New York
Employees: 11-50
Founded date: 2011
Investment Type: Venture Capital

Mentions in press and media 3

DateTitleDescription
24.01.2025Kexing Biopharm Participates in the 17th Biotech Showcase, with Multiple Innovation Pipelines Gaining AttentionSHENZHEN, China, Jan. 24, 2025 /PRNewswire/ -- From January 13 to 16, Dr. Huiming Li, Deputy General Manager of Kexing Biopharm New Drug Research Center, attended the 17th Biotech Showcase Conference in San Francisco and the Global Biopharm...
31.10.2023BioLineRx Entered Exclusive License Agreement to Motixafortide in Asia, Advised by MSQ VenturesNEW YORK, Oct. 31, 2023 /PRNewswire/ -- MSQ Ventures ("MSQ") is pleased to announce that its client, BioLineRx Ltd. ("BioLineRx") (NASDAQ/TASE: BLRX), has entered into an exclusive license agreement with Guangzhou Gloria...
29.06.2022BioLineRx Enters Co-Development Agreement with GenFleet to Further Develop Motixafortide in Pancreatic Ductal Adenocarcinoma (PDAC), Advised by MSQ VenturesNEW YORK, June 29, 2022 /PRNewswire/ -- M.S.Q. Ventures ("MSQ") is pleased to announce that its client, BioLineRx Ltd. ("BioLineRx") (NASDAQ/TASE: BLRX), has successfully entered into a co-development agreement with GenF...

Reviews 0

Sign up to leave a review

Sign up Log In